The AIM HIGH study was a primary concern for some AMRN investors with the viability of amrn 101 use in primary care. With the less than successful Fibric Acid results in the ACCORD study Niaspan was the dominant competitor for amrn 101. A successful AIM HIGH trial would have caused me to sell my AMRN position as proven OUTCOME benefits would be a very powerful reason to use Niaspan since it has powerful LDL lowering, HDL raising and Trig lowering properties. Lack of outcome benefits and ? ischemic stroke risk will favor amrn101 use significantly. And if outcome studies are similar to Jelis for amrn then this will become a blockbuster. I think that is why AMRN spiked up today.
Market Data 
Markets 
AI
